Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lenvatinib mesylate

View Patient Information
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib mesylate blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:E7080 mesylate
multi-kinase inhibitor E7080 mesylate
US brand name:Lenvima
Chemical structure:4-[3-chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide mesylate
6-quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, methanesulfonate (1:1)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search